HCC is not sensitive to chemotherapy, and targeted drugs such as sorafenib and regorafenib have certain benefits, but far below clinical expectations.45, 46 Since PLK4 is abnormally activated and plays an oncogenic role in part of HCC, it is likely to be a therapeutic target for HCC. Here, PLK4 is linked to hepatocellular carcinoma.